Clinical Trials Using CDK2/5/9 Inhibitor CYC065
Clinical trials are research studies that involve people. The clinical trials on this list are studying CDK2/5/9 Inhibitor CYC065. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers
This is an open-label, single arm, dose escalation study in patients with advanced cancers.
Location: 2 locations
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed / Refractory CLL
A Phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Location: M D Anderson Cancer Center, Houston, Texas